Michael H. Davidson sold $11M of NAMS
Chief Executive Officer at NewAmsterdam Pharma Co N.V.. 306,293 shares at an average of $34.53, traded Feb 24, 2026, filed Feb 26, 2026.
Score components
- +25RoleCEO
- +25Trade size$10.6M at market
- +20Share of holdings soldSold 58% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-078718, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | MOption exercise Ordinary Shares10b5-1 | +64,708 | - | - | 524,567 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -61,547 | $36.13 | $2.2M | 463,020 | Feb 26, 2026 |
| Feb 24, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -3,161 | $36.46 | $115k | 459,859 | Feb 26, 2026 |
| Feb 25, 2026 | MOption exercise Ordinary Shares10b5-1 | +58,253 | - | - | 518,112 | Feb 26, 2026 |
| Feb 25, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -46,517 | $35.11 | $1.6M | 471,595 | Feb 26, 2026 |
| Feb 25, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -10,436 | $35.96 | $375k | 461,159 | Feb 26, 2026 |
| Feb 25, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -1,300 | $36.68 | $48k | 459,859 | Feb 26, 2026 |
| Feb 26, 2026 | MOption exercise Ordinary Shares10b5-1 | +183,332 | - | - | 643,191 | Feb 26, 2026 |
| Feb 26, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -165,408 | $33.63 | $5.6M | 477,783 | Feb 26, 2026 |
| Feb 26, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -17,924 | $34.44 | $617k | 174,144 | Feb 26, 2026 |
| Feb 24, 2026 | MOption exercise Option (right to buy)derivative10b5-1 | -64,708 | $0.00 | $0 | 924,559 | Feb 26, 2026 |
| Feb 25, 2026 | MOption exercise Option (right to buy)derivative10b5-1 | -58,253 | $0.00 | $0 | 866,306 | Feb 26, 2026 |
| Feb 26, 2026 | MOption exercise Option (right to buy)derivative10b5-1 | -183,332 | $0.00 | $0 | 682,974 | Feb 26, 2026 |
Related signals
Other insiders at NewAmsterdam Pharma Co N.V. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $1.3M 50,246 shares | -42% | |
| 38Weak | NAMSbuy NewAmsterdam Pharma Co N.V. | Michael H. Davidson Chief Executive Officer | $227k 10,000 shares | +1% | |
| 26Weak | NAMSsell NewAmsterdam Pharma Co N.V. | John W Smither director | $41k 1,600 shares | -15% | |
| 75Notable | NewAmsterdam Pharma Co N.V. | Louis G Lange director | $1.4M 44,619 shares | -81% | |
| 73Notable | NewAmsterdam Pharma Co N.V. | Louis G Lange director | $829k 28,186 shares | -100% | |
| 40Moderate | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $9.1M 300,000 shares | -173% | |
| 70Notable | NewAmsterdam Pharma Co N.V. | Michael H. Davidson Chief Executive Officer | $15M 443,707 shares | -72% | |
| 65Notable | NewAmsterdam Pharma Co N.V. | Johannes Jacob Pieter Kastelein Chief Scientific Officer | $1.6M 45,481 shares | -46% | |
| 25Weak | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $2.3M 72,428 shares | -113% | |
| 25Weak | NewAmsterdam Pharma Co N.V. | Louise Frederika Kooij Chief Accounting Officer | $2.4M 72,572 shares | -116% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.